Bruker BioSciences Reports Significantly Improved Earnings and Cash Flows on Record Revenue of $297.6 Million For Full Year 2005

Share Name	Share Symbol	Market	Type
Bruker Corporation	NASDAQ:BRKR	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	2.84	4.48%	66.25	65.74	66.73	66.52	63.0101	63.89	695,554	22:34:03

Bruker (NASDAQ:BRKR)
Historical Stock Chart

From Jul 2019 to Jul 2024

Company Reports Four Profitable Quarters and $41 Million Cash Flow from Operations in 2005 Bruker BioSciences Corporation (NASDAQ: BRKR) today reported fourth quarter 2005 revenue of $80.6 million, compared to revenue of $85.6 million in the fourth quarter of 2004. Excluding foreign currency effects, revenue increased by 1%. For the full year 2005, revenue increased 5% to $297.6 million, compared to $284.4 million for the year 2004. Foreign currency effects did not have a material impact on full year revenue. GAAP net income in the fourth quarter of 2005 was $1.9 million, or $0.02 per diluted share, compared to a net loss in the fourth quarter of 2004 of ($0.9) million, or ($0.01) per diluted share. GAAP net income for the full year 2005 was $3.6 million, or $0.04 per diluted share, compared to a net loss of ($7.8) million, or ($0.09) per diluted share, for the full year 2004. During the fourth quarter of 2005, positive operating cash flow of $15.4 million increased our cash position to $99.7 million. Cash generated from operations was $41.0 million for the full year 2005, compared to a use of cash of ($0.9) million during the full year 2004, and adjusted EBITDA was $26.9 million for the full year 2005, compared to $16.8 million for 2004. Commenting on the fourth quarter and year 2005, Frank Laukien, President and CEO, said: "We have made solid progress in 2005, and I am particularly pleased with our improved profitability and good cash flow in the fourth quarter. Throughout the year 2005, we have improved our operating income and net income by growing revenue, improving our gross margins and by reducing expenses. Our continued commitment to improve our financial performance has resulted in four consecutive quarters of profitability." He continued: "I am also encouraged by the recent considerable strength in our new order bookings and our healthy year-end backlog. We believe that our performance-leading products and solutions, our strengthened global sales and service capabilities, and the additional technologies and accessible market segments from our recent acquisitions position us well for the future. Our financial goals for 2006 are: -- revenue growth of approximately 10% compared to 2005, -- at least a doubling of our 2005 EPS, and -- continued strong cash flows from operations. Looking further ahead, in 2007 we expect to reach industry-standard profitability, while maintaining above industry-standard top-line growth." William Knight, Chief Financial Officer, commented: "In addition to continuing improvements in our profitability during 2005, I am also pleased to see our strong cash position at the end of the year, even after closing two acquisitions in November 2005, and our strengthened balance sheet. We are entering 2006 with a solid backlog, positive momentum from our strong fourth quarter order bookings and exciting new products and market opportunities. We are optimistic that in 2006 our core businesses, as well as the additional market segments that we have entered via our recent acquisitions, will both contribute to above industry-average top-line growth and continued improvements in profitability." OPERATING BUSINESSES Set forth below is selected financial information for Bruker BioSciences' two operating businesses: Bruker Daltonics (life science mass spectrometry and NBC detection tools business) and Bruker AXS (life science, materials research and industrial x-ray analysis tools business): BRUKER DALTONICS For the year 2005, revenue for the Bruker Daltonics business increased 6% to $161.4 million, from $152.6 million in 2004, and foreign currency effects were not material. For the year 2005, Bruker Daltonics' revenue was derived 68% from life-science mass spectrometry systems, 12% from NBC detection systems, and 20% from after-market sales. Adjusted EBITDA was $22.1 million for the full year 2005, compared to $15.4 million for 2004. BRUKER AXS For the year 2005, revenue for the Bruker AXS business increased 4% to $137.4 million, from $132.6 million in 2004, and foreign currency effects were not material. For the year 2005, Bruker AXS' revenue was derived 75% from systems sales and 25% from after-market sales. Adjusted EBITDA was $7.6 million for the full year 2005, compared to $4.8 million for 2004. USE OF NON-GAAP FINANCIAL MEASURES In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP measure of Adjusted EBITDA. Adjusted EBITDA is defined as US GAAP operating income (loss) excluding depreciation and amortization expense and write-down of demonstration equipment to net realizable value. We believe that the inclusion of this non-GAAP measure helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company's performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measure included in this press release is not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of this non-GAAP financial measure to the most directly comparable GAAP financial measures are set forth in the accompanying tables. EARNINGS CONFERENCE CALL Bruker BioSciences will host an operator-assisted earnings conference call at 11 a.m. Eastern Standard Time on Thursday, February 23, 2006. To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada. Investors should refer to the Bruker BioSciences Quarterly Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 55966589. ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. Condensed consolidated statements of operations, operating business information, and balance sheets follow for Bruker BioSciences Corporation. -0- *T Bruker BioSciences Corporation CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Three Months Ended Year Ended December 31, December 31, ----------------- ----------------- 2005 2004 2005 2004 -------- -------- -------- -------- Product revenue $ 71,037 $ 75,222 $259,645 $249,929 Service revenue 9,377 9,444 35,856 32,298 Other revenue 141 972 2,068 2,189 -------- -------- -------- -------- Total revenue 80,555 85,638 297,569 284,416 Cost of product revenue 39,372 41,373 147,364 145,188 Cost of service revenue 7,718 6,547 24,398 20,752 -------- -------- -------- -------- Total cost of revenue 47,090 47,920 171,762 165,940 -------- -------- -------- -------- Gross profit margin 33,465 37,718 125,807 118,476 Operating Expenses: Sales and marketing 14,056 17,160 51,438 55,976 General and administrative 5,742 5,884 22,374 20,399 Research and development 9,406 12,129 41,357 43,219 -------- -------- -------- -------- Total operating expenses 29,204 35,173 115,169 119,594 -------- -------- -------- -------- Operating income (loss) 4,261 2,545 10,638 (1,118) Interest and other income (expense), net 310 (1,011) 1,311 (3,779) -------- -------- -------- -------- Income (loss) before income tax provision and minority interest in consolidated subsidiaries 4,571 1,534 11,949 (4,897) Income tax provision 2,795 2,470 8,263 2,865 -------- -------- -------- -------- Income (loss) before minority interest in consolidated subsidiaries 1,776 (936) 3,686 (7,762) Minority interest in consolidated subsidiaries (91) (76) 40 69 -------- -------- -------- -------- Net income (loss) $ 1,867 $ (860) $ 3,646 $ (7,831) ======== ======== ======== ======== Net income (loss) per share: Basic $ 0.02 $ (0.01) $ 0.04 $ (0.09) ======== ======== ======== ======== Diluted $ 0.02 $ (0.01) $ 0.04 $ (0.09) ======== ======== ======== ======== Weighted average shares outstanding: Basic 89,665 89,470 89,521 88,495 ======== ======== ======== ======== Diluted 89,859 89,470 89,828 88,495 ======== ======== ======== ======== Bruker BioSciences Corporation BRUKER BIOSCIENCES SELECTED BUSINESS INFORMATION (in thousands) Three Months Ended Year Ended December 31, December 31, ----------------- ----------------- 2005 2004 2005 2004 -------- -------- -------- -------- Total revenue $ 80,555 $ 85,638 $297,569 $284,416 ======== ======== ======== ======== Operating income (loss) $ 4,261 $ 2,545 $ 10,638 $ (1,118) Depreciation and amortization 1,907 3,007 8,559 9,494 Write-down of demonstration equipment 1,977 1,991 7,666 8,441 -------- -------- -------- -------- Adjusted EBITDA $ 8,145 $ 7,543 $ 26,863 $ 16,817 ======== ======== ======== ======== Bruker BioSciences Corporation BRUKER DALTONICS SELECTED OPERATING BUSINESS INFORMATION (in thousands) Three Months Ended Year Ended December 31, December 31, ----------------- ----------------- 2005 2004 2005 2004 -------- -------- -------- -------- Total revenue $ 44,402 $ 44,664 $161,356 $152,592 ======== ======== ======== ======== Operating income $ 5,537 $ 2,279 $ 12,430 $ 4,063 Depreciation and amortization 1,053 2,009 4,983 5,736 Write-down of demonstration equipment 1,249 1,326 4,726 5,606 -------- -------- -------- -------- Adjusted EBITDA $ 7,839 $ 5,614 $ 22,139 $ 15,405 ======== ======== ======== ======== Bruker BioSciences Corporation BRUKER AXS SELECTED OPERATING BUSINESS INFORMATION (in thousands) Three Months Ended Year Ended December 31, December 31, ----------------- ----------------- 2005 2004 2005 2004 -------- -------- -------- -------- Total revenue $ 36,838 $ 41,772 $137,357 $132,622 ======== ======== ======== ======== Operating income (loss) $ (776)$ 1,797 $ 1,059 $ (1,744) Depreciation and amortization 854 998 3,576 3,758 Write-down of demonstration equipment 728 665 2,940 2,835 -------- -------- -------- -------- Adjusted EBITDA $ 806 $ 3,460 $ 7,575 $ 4,849 ======== ======== ======== ======== Bruker BioSciences Corporation CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) December 31, ------------------ 2005 2004 -------- -------- ASSETS Current assets: Cash and short-term investments $ 99,681 $ 77,691 Accounts receivable, net 53,744 57,792 Due from affiliated companies 4,860 9,530 Inventories 96,333 107,748 Other current assets 11,094 18,530 -------- -------- Total current assets 265,712 271,291 Property and equipment, net 72,336 84,990 Intangible and other assets 22,839 15,266 -------- -------- Total assets $360,887 $371,547 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term borrowings $ 8,002 $ 12,205 Accounts payable 14,117 22,652 Due to affiliated companies 3,857 3,026 Other current liabilities 85,551 73,277 -------- -------- Total current liabilities 111,527 111,160 Long-term debt 21,423 27,763 Other long-term liabilities 19,901 15,156 Minority interest in subsidiaries 233 193 Total shareholders' equity 207,803 217,275 -------- -------- Total liabilities and shareholders' equity $360,887 $371,547 ======== ======== *T

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BRKR Bruker Corporation